Status:
COMPLETED
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).
Eligibility Criteria
Inclusion
- The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria.
- The patient must have active disease at both Screening and predose on Day 1 of Period 1.
- Patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance.
Exclusion
- Pregnant or lactating women
- Serious medical conditions that would make treatment with CP-690,550 potentially unsafe.
- A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT01484561
Start Date
April 1 2012
End Date
February 1 2013
Last Update
April 2 2014
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
South Miami, Florida, United States, 33143
2
Pfizer Investigational Site
Albany, New York, United States, 12206
3
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635
4
Pfizer Investigational Site
Dallas, Texas, United States, 75231